NEWS
CONTENTS
CONTACT

HARAKENZO
WORLD PATENT & TRADEMARK


OSAKA
HEAD OFFICE

DAIWA MINAMIMORIMACHI BLDG.,
2-6, 2-CHOME-KITA, TENJINBASHI,
KITA-KU,OSAKA 530-0041 JAPAN
TEL:+81-6-6351-4384
(Main Number)
FAX:+81-6-6351-5664
(Main Number)
E-Mail:

TOKYO
HEAD OFFICE

WORLD TRADE CENTER BLDG. 21F,
2-4-1, HAMAMATSU- CHO, MINATO-KU,
TOKYO 105-6121,JAPAN
TEL:+81-3-3433-5810
(Main Number)
FAX:+81-3-3433-5281
(Main Number)
E-Mail:


HIROSHIMA
OFFICE

NOMURA REAL ESTATE HIROSHIMA BLDG. 4 F, 2-23 TATEMACHI, NAKA-KU, HIROSHIMA CITY, HIROSHIMA 730-0032, JAPAN
TEL:+81-82-545-3680
(Main Number)
FAX:+81-82-243-4130
(Main Number)
E-Mail:

To be opened
on March.1.2018

NAGOYA
OFFICE

GLOBAL GATE 9F, 4-60-12 HIRAIKE-CHO, NAKAMURA-KU, NAGOYA-SHI, AICHI 453-6109, JAPAN
TEL:+81-52-589-2581
(Main Number)
FAX:+81-52-589-2582
(Main Number)
E-Mail:


In the background of the HARAKENZO trademark is a global map wherein countries/regions are sized according to the number of patents registered there in 1991.

Privacy policy


NEWS
IP News index

EU Pharmaceutical Industry Expresses Its View on EU’s Pharmaceutical Strategy and IP Action Plan

On November 25, 2020, The European Federation of Pharmaceutical Industries and Associations (EFPIA) issued a statement on “IP Action Plan” which was announced by the European Commission on the same date.
The EFPIA welcomed the unified system of patent term extension included in the Plan. On the other hand, it expressed a concern that European Commission is considering coordination among EU member states at the early stage, systems of sharing information, etc. under compulsory licensing in emergency situations such as “the COVID-19 crisis.”
The EFPIA stated that compulsory licensing is not an effective policy tool and seeking to actively make use of it is disincentive to investment in research and development


https://www.jetro.go.jp/biznews/2020/12/8f91b436876aeb5f.html













































IP News index
PAGE TOP
Intellelution.com